NCT06344247View on ClinicalTrials.gov

Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease

NARecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

September 1, 2025

Study Completion Date

December 1, 2025

Conditions
ObesityChronic Kidney Diseases
Interventions
DRUG

RAS inhibitors：Losartan®️/Valsartan®️

Losartan®️/Valsartan®️ : maintain the maximum dose/maximum tolerated dose.

DRUG

dapagliflozin：Forxiga®️

Forxiga®️ : titrated to the target dose (10 mg qd).

DRUG

simagliptin：Forxiga®️

Semaglutide®️ : titrated to the target dose (1 mg qw).

Trial Locations (1)

200127

RECRUITING

Renji Hospital Affiliated to Shanghai JIAO TONG University school of medicine, Shanghai

All Listed Sponsors
lead

RenJi Hospital

OTHER